JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3012 Ruxolitinib (INCB018424)
4 Citation

Target: JAK

Summary: JAK inhibitor

insoluble in H2O; ≥15.32 mg/mL
A4135 Tofacitinib (CP-690550) Citrate
2 Citation

Target: JAK

Summary: Potent JAK inhibitor

≥25.22 mg/mL
A4317 Apremilast (CC-10004)

Target: Phosphodiesterases (PDEs)

Summary: PDE4 inhibitor

≥23.05 mg/mL
A1926 CA 074
2 Citation

Target: Cathepsins

Summary: Cathepsin B inhibitor

≥19.17 mg/mL
B1112 Merimepodib

Target: IMPDH

Summary: Novel noncompetitive inhibitor of IMPDH(Inosine monophosphate dehydrogenase).

≥45.2 mg/mL
B4664 T-5224
10 Citation

Target: AP-1|MMP

Summary: C-Fos/AP-1 inhibitor

≥25.88 mg/mL
A8332 R788 disodium

Target: Syk

Summary: Syk inhibitor,ATP competitive and potent

≥62.4 mg/mL
A8686 VX-745

Target: p38

Summary: P38α inhibitor,highly potent and selective

≥21.8 mg/mL
B2284 Fostamatinib (R788)

Target: Syk

Summary: Spleen tyrosine kinase (Syk) inhibitor

insoluble in H2O; ≥100.4 mg/mL
A5176 AS-605240

Target: PI3K

Summary: Potent and selective PI 3-Kγ inhibitor

insoluble in H2O; insoluble in EtOH; ≥4.28 mg/mL